Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
Completed · Phase 4
Conditions studied: Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
In brief
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia. The primary hypothesis is that quetiapine treatment will be associated with a decrease in substance use.
Key facts
- Study ID
- NCT00156715
- Run by
- Dartmouth-Hitchcock Medical Center
- People needed
- 23
- Starts
- 2004-03-01
- Expected to finish
- 2008-10-01
- Last updated by the study team
- 2018-03-14
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-65
- Schizophrenia or schizoaffective disorder
- Meets Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) criteria for a substance use disorder (alcohol use disorder [AUD]; abuse or dependence)
- Active substance use on at least 8 days during the 4 weeks prior to randomization.
- Current treatment with antipsychotic medication.
- Able to provide informed consent, or in the case of patients with legal court appointed guardians willing to give assent, with the consent of the guardian.
- Not actively suicidal.
You may not qualify if…
- Current treatment with, decanoate antipsychotic, clozapine, or doses of quetiapine not approved by the team of investigators. Individuals treated with depot antipsychotic must wait until the end of their injection cycle before starting on study medication.
- Currently pregnant, planning to become pregnant, or unwilling to use an acceptable form of birth control.
- Currently residing in a residential program designed to treat substance use disorders.
- Treatment at baseline with a psychotropic agent proposed to curtail substance use.
- Patients who, in the opinion of the investigator, are judged unsuitable to participate in the study.
- Unable to take part in the assessments in a meaningful way
- Hypersensitivity/intolerance to quetiapine
- Serious, unstable medical condition
- Participation in clinical trial of an investigational drug within 30 days of baseline visit, or concurrent participation in a treatment study of a psychosocial intervention
Where it is running
- Medical College of Georgia — Augusta, Georgia, United States
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
- West Central Behavioral Health — Lebanon, New Hampshire, United States
- Mental Health Center of Greater Manchester — Manchester, New Hampshire, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.